Background: Remote ischemic preconditioning (RIPC) may protect the spinal cord from ischemic injury. This randomized clinical trial was designed to assess whether a large clinical trial testing the effect of RIPC on neurologic outcome in patients undergoing spine surgery is warranted. This trial was registered with ClinicalTrials.gov, number NCT00778323.
S
pinal cord ischemia-reperfusion injury is a leading cause of paraplegia after spinal surgery. The incidence of paraplegia was 11.8% after posterior longitudinal ligament surgery. 1 Spinal cord ischemia is a potential mechanism in the pathophysiology of cervical spondylotic myelopathy (CSM). 2 Decompression surgery is the gold standard for treatment for CSM, but decompression surgery can induce ischemia-reperfusion injury. According to previous reports, the incidence of neurologic complications after cervical decompression surgery (paresis, palsy, etc) due to spinal cord ischemia-reperfusion injury ranges from 2% to 5.7%. 3, 4 Ischemic preconditioning (IPC) is proven to minimize ischemia-reperfusion injury in many organs including the spinal cord in animal models. 5, 6 Unfortunately, the idea of exposure to brief periods of ischemia before an anticipated spinal cord ischemic event is not clinically practical. Recently, a new phenomenon, known as remote IPC (RIPC), was found to induce ischemic tolerance not only within the same piece of tissue, but also in distant tissues as well as distant organs. 7 RIPC has greater potential for clinical application than classic IPC. It can be performed in a nonvital organ, avoiding the high risk of preconditioning in the vital organ, such as the spinal cord. As it is a more amenable and less invasive approach, this new promising and intriguing strategy has been applied in clinical experiments firstly during coronary arterial surgery with exciting results. 8, 9 However, whether RIPC is beneficial on spinal cord ischemia-reperfusion injury for patients with CSM undergoing elective cervical decompression surgery remains unknown. Depending upon the types of spinal surgery undertaken, and the associated complication rates, research designed to detect even a large effect of a new drug or therapy (eg, a 50% reduction in complication rate) could easily require more than 1000 patients per group.
Our strategy for assessing the advisability of such a large clinical trial was to postulate that if RIPC increased markers of neuronal ischemia and delayed rate of recovery after cervical decompression surgery in a small clinical trial, a large clinical trial would not be warranted. In contrast, if RIPC decreased the markers of neuronal ischemia and increased rate of recovery, a large clinical trial would be warranted. The primary assay employed in the current study is changes in serum biomarkers. There are a few biomarkers to be used for evaluating the severity of central nervous system (CNS) injury (eg, traumatic brain injury, cerebral infraction, and spinal cord injury). Among these, neuron-specific enolase (NSE) and S-100B have attracted much attention as potentially useful diagnostic biomarkers for brain and spinal cord injuries. The increases of S-100B and NSE at early stage of injury are closely related to the neurologic dysfunction at late stage. 10 At 20 patients per group, this strategy entailed the risk of obtaining an intermediate result that would not justify a recommendation for or against a large clinical trial, but given the negligible cost and expected low complication rate of three 5-minute cycles of upper limb ischemia, we felt that the risk of an indeterminate result was outweighed by the probability of a result that would warrant a recommendation.
We therefore designed this small clinical trial to assess whether a large clinical trial testing the effect of RIPC on neurologic outcome in patients undergoing spinal surgery is warranted.
MATERIALS AND METHODS

Patients
This prospective randomized clinical study was conducted between June 2007 and October 2008 in Xijing Hospital (one of the state's largest hospital in northwestern China). The hospital board of ethics approved the trial, and informed consent concerning all issues was obtained. Staff involved in the clinical care and members of the study group obtaining functional data were blinded to randomization for the period of data acquisition and analysis. The power of inequality test is set as 0.8 (a = 0.05). Referring to our preliminary study, we assumed a difference in S-100B and NSE in serum of about 0.7 and 8 mg/L between the RIPC group and control group. The Produce Application and Support Software (Prentke Romich Company, Wooster, OH) was used to calculate the sample size. We recruited 40 consecutive adult patients presenting with clinical and radiologic signs of CSM over a 0.5-year period. Cord compression was documented by magnetic resonance imaging and/or computerized tomography. Disease duration ranged from 6 to 24 months. We excluded those older than 75 years, those with heart, hepatic, renal or pulmonary diseases, and those with peripheral vascular diseases affecting the upper limbs. Patients were randomly assigned to either a RIPC group (n = 20) or a control group (n = 20) before induction of anesthesia.
Procedures
RIPC consisted of three 5-minute cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 minutes of reperfusion during, which the cuff was deflated. 9 Control patients had a deflated cuff placed on the right upper arm for 30 minutes. The RIPC protocol was applied after anesthesia induction and before surgery started. Patients and the orthopedic surgeons were blinded to treatment allocation. The anesthesiologists were blinded to treatment allocation by hiding the cuff-inflator and cuff. Data collectors were blinded to the assignment of patients and the results were compared and analyzed blindly.
On arrival in the anesthetic room, a peripheral venous cannula was inserted and patients were sedated intravenously with midazolam. An arterial cannula was inserted before anesthesia for arterial blood pressure monitoring and blood samples. Nasopharyngeal temperature was monitored continuously during the operation.
Anesthesia was induced with midazolam (0.05 mg/ kg) with propofol (1.5-2 mg/kg), fentanyl (2-4 mg/kg), and vecuronium (0.1 mg/kg). The trachea was intubated with a GlideScope Video Laryngoscope (GVL, Canada) for cervical spine immobilization and mechanical ventilation was started with oxygen with or without room air to achieve an end-tidal carbon dioxide tension of 30 to 37.5 mmHg. Anesthesia was maintained with total intravenous propofol infusion (125-225 mg/kg/min) technique augmented with remifentanil (0.15-0.3 mg/kg/min) and vecuronium as needed. Volatile anesthetic agents and nitrous oxide were avoided entirely to maximize somatosensory-evoked potential (SEP) amplitudes.
All patients were surgically treated via an anterior approach, either by anterior cervical discectomy and fusion with instrumentation or by cervical corpectomy and fusion with instrumentation and followed-up postoperatively at 7 days and then at 1, 3, and 6 months. The Japanese Orthopaedic Association (JOA) forms were completed by the patients under the supervision of a nonbiased reviewer.
Sample Collection and Biochemical Measurements
Blood samples for measurements of S-100B and NSE were taken before the induction of anesthesia, before decompression, after decompression, 6 hours and 1, 3, 5, 7 days after surgery. Samples were inverted gently several times and allowed to clot for 30 minutes at room temperature. Blood samples were centrifuged at 1500 rpm for 15 minutes to obtain serum. Serum samples were then stored at À 801C before analysis. Serum samples that contained significant red blood cell hemolysis were excluded.
Serum concentrations of S-100B and NSE were assayed by use of commercially available sandwich technique enzyme-linked immunosorbent assay kits (BioVendor, Czech Republic for S-100B; ADI for NSE).
Determinations of the concentrations of S-100B and NSE in serum were performed on a LIAISON Random Access Analyzer (DiaSorin SpA, Saluggia, Italy). The detection limit for Liaison Sangtec 100 was 0.02 mg/L, both intraassay and interassay variations were less than 11%. For NSE, the intraassay and interassay variations were less than 6%.
Neurophysiologic Monitoring
Neurophysiologic monitoring was performed using a 16-channel Axon Epoch XP (Axon Systems, Inc, Version 1.25). A senior electrophysiologist performed all evoked potential monitoring, by using median nerve SEPs according to standard variables for stimulating and recording. Median nerve SEPs were recorded at all time points. The recordings were observed for the presence of the main peaks, N20 and P25. The observed parameters for cortical response were peak-to-peak amplitudes, peak latencies, and wave differentiation. The amplitude and latency of the N20-P25 complex were measured. The median nerve was stimulated at the wrist using a pair of surface bar electrodes, with 0.2 milliseconds square wave electrical pulses at 3.1 Hz. The cathode was placed 2.5 cm proximal to the anode. The stimulus intensity for conscious subjects was adjusted to produce a visible thumb twitch without causing discomfort. The recording electrodes were placed at C3 and C4 with the reference electrode at Fz, according to the international 10 to 20 system. The recordings were averaged over 200 consecutive sweeps and visually analyzed for the presence of the main peaks N20-P25. SEP waves were recorded and classified before surgery as follows: Type I, wave configuration was normal, N20 latency did not exceed 10% prolongation, and N20-P25 amplitude was larger than 0.5 mV; Type II, one of the parameters involving amplitude or latency was abnormal; Type III, the waveform could be detected and measured, but both latency and amplitude were abnormal; Type IV, the waveform was unidentifiable or disappeared altogether (Fig. 1) . 11 Intraoperative SEP monitoring was conducted continuously during the surgery. Initial recordings, made after induction of anesthesia and before positioning, served as intraoperative baselines. SEPs were collected continuously (B1 average every 40 s) throughout the procedure. Reduction in amplitude of the cortical complex by greater than 50% or prolongation of response in peak latency by greater than 10% unrelated to changes in anesthesia during surgery was viewed as being significant, and the surgeon was informed.
Neurologic Functional Status
We used a JOA scale (Table 1) to evaluate the neurologic functional status before surgery and at postoperative follow-up at 7 days and at 1, 3, and 6 months. To rate surgical outcome, a recovery rate (RR) after 
Statistical Analysis
Demographic and operative data are presented as mean ± SD. The levels of S-100B and NSE are represented as mean ± SEM. Comparison between treatment groups was made with the unpaired student t test. A value of P<0.05 was regarded as significant. The recovery ratios of 2 groups were compared by the Kruskal-Wallis nonparametric test. Patients were randomly assigned to groups by random numbers table. Statistical analysis of the data was performed using commercially available software program SPSS version 11.5. This trial is registered with ClinicalTrials.gov, number NCT00778323. Figure 2 shows the trial protocol. Fifty-one patients were assessed for eligibility, of whom 40 were actually recruited and randomly assigned to RIPC group (n = 20) or control group (n = 20). In an almost 1.5-year period, 40 patients were enrolled in this prospective study, and received the intended treatment, completed the study protocol, and were included in the analysis. Surgery consisted of anterior decompression performed by an experienced team of orthopedic surgeons. No significant intraoperative or postoperative complications were documented in all patients. Baseline characteristics (Table 2) and operative data (data not shown) were similar in both groups.
RESULTS
Trial Protocol
SEP Detection and Monitoring
According to SEP classification, normal SEPs were recorded in 12 patients (60%) in the control group and 13 patients (65%) in the RIPC group, respectively, and abnormal SEPs in the other 15 patients in the 2 groups.
There were 4 patients (20%) with type IIa SEPs, 3 patients (15%) with type IIb, and 1 patient (5%) with type III in the control group. In the RIPC group, 4 patients (20%) were recorded for Type IIa, 2 (10%) for Type IIb, and 1 (5%) for Type III. There were no differences in SEP classification between the 2 groups.
In the 2 groups (40 patients), 4 instances of transient significant SEP changes were observed. One case in the control group and 2 cases in the RIPC group were attributed to the result of hyperextension of the neck, which resolved with repositioning, and 1 case in the control group was related to arm position during surgery, which resolved with arm repositioning. After the aforementioned interventions, SEP signal changes normalized and returned to baseline for all patients. None of these patients had a postoperative neurologic deficit.
Neurologic Function Recovery
There was no significant difference in preoperative JOA score between control and RIPC groups ( Table 2 ). The recovery ratios of the 2 groups during the follow-up time period after surgery are shown in Figure 3 . At 7 days and 1 and 3 months after surgery, there were significant differences in the recovery ratios between control and RIPC groups (Kruskal-Wallis test, P<0.05), but there were no statistically significant differences at 6 months between both groups. cervical decompression surgery. In most patients, blood concentrations of S-100B and NSE increased during the surgical decompression. The reduction in serum S-100B concentrations in patients treated with RIPC was significant at 6 hours (0.101 ± 0.007 mg/L with RIPC vs. 0.177 ± 0.024 mg/L with control; P = 0.007), 1 day (0.096 ± 0.030 mg/L vs. 0.167 mg/L ± 0.027; P = 0.018) after surgery. RIPC significantly reduced serum NSE release at 6 hours (9.02 ± 0.75 mg/L with RIPC vs. 14.32 ± 1.27 mg/L with control; P = 0.001), 1 day (9.76 ± 0.71 mg/L vs. 14.79 ± 1.29 mg/L; P = 0.002), 3 days (9.86 ± 0.72 mg/L vs. 13.98 ± 1.18 mg/L; P = 0.006), 5 days (9.14 ± 0.80 mg/L vs. 12.99 ± 0.99 mg/L; p = 0.004) after surgery. There were significant differences in serum NSE concentrations at 6 hours, 1, 3, and 5 days after surgery between the 2 groups (P<0.05).
Serum S-100B and NSE Levels
DISCUSSION
Our study has shown that RIPC, mediated by transient upper limb ischemia, can reduce serum levels of S-100B and NSE in the perioperative period in adult CSM patients undergoing elective cervical decompression surgery. The neurologic recovery in RIPC group was better than that in the control group at 7 days, and 1 and 3 months after surgery. The present results strongly support the need for a large-scale multicenter clinical trial to determine reliably whether there is real benefit from this simple alternative preconditioning to reduce spinal cord ischemia-reperfusion injury in elective cervical decompression surgery.
Classic IPC was first described in myocardium ischemia, and then extended to many other organs including brain and spinal cord. 5, 6 Direct surgical preconditioning has been demonstrated in the context of coronary artery bypass surgery. 13 However, a local IPC in a vital organ is invasive and impractical in the clinic. Our previous studies have shown that some non-IPC methods can also induce spinal cord ischemic tolerance, such as hyperbaric oxygen (HBO) and isoflurane preconditioning. [14] [15] [16] Nevertheless, HBO and anesthetics preconditioning are still difficult to perform before the surgery as they require specialist equipment, such as an HBO chamber. More recently, attention has been turned to the potential systemic benefits of brief periods of ischemia in a distant tissue or organ, the so-called RIPC. In animal models, preconditioning of mesenteric or renal arteries and lower limb reduced cardiac, cerebral, and spinal cord injury. [17] [18] [19] Although RIPC was first applied to clinical studies during coronary arterial surgery and obtained exciting results, 8, 9 there were little clinical data on the neuroprotective effects of RIPC against spinal cord ischemia-reperfusion injury. The current study is the first randomized clinical trial on the neuroprotection of RIPC against spinal cord injury.
Monitoring the levels of neuron-specific or astroglia-specific proteins in the serum and cerebrospinal fluid (CSF) is a useful approach for evaluating the severity of CNS injury (eg, traumatic brain injury, cerebral infraction, and spinal cord injury). Among a number of biomarkers, NSE and S-100B have attracted much attention as potentially useful diagnostic biomarkers for brain and spinal cord injuries. In previous reports, biomarkers such as S-100B and NSE are increased at early stages of neuronal injury and are closely related to neurologic dysfunction at late stages. 10 The cytoplasmic enzyme, NSE is normally found in neurons and neuroendocrine cells. S-100B is a Ca 2+ -binding protein that is thought to be involved in a number of Ca 2+ -dependent cellular functions. Many previous studies have demonstrated that increases of NSE and S-100B in CSF and peripheral blood are positively correlated with the severity of CNS injury but negatively correlated with the outcome. 20 A recent study found that the NSE and S-100B protein levels in serum, as well as those in CSF, can be used as specific biomarkers for the acute phase of spinal cord injury. 21 In the current study, we found that both the S-100B and NSE levels in serum were elevated during the surgical decompression. The elevation of S-100B was sustained to 1 day after decompression surgery, whereas the elevation of NSE was sustained to 5 days after the surgery. This indicates that acute ischemiareperfusion spinal cord injury occurred after cervical decompression surgery. The S-100B and NSE contents in serum were significantly reduced by RIPC pretreatment during the perioperative episode.
As a commonly used assessment method of the severity of symptoms in patients with CSM, JOA score was used in our study. JOA score assesses the upper limb, lower limb, and sphincter functions of patients. It is useful in preoperative assessment and also to monitor the neurologic recovery postoperatively. 22 It has been reported that JOA score gradually improved and usually reached a plateau at 6 months after the cervical decompression surgery. In our study, we demonstrated improvement in upper limbs and lower limbs functions in terms of the JOA score after surgical decompression in both control group and RIPC group. The RR in RIPC group is higher than that in control group at 7 days, and 1 and 3 months after decompression. This result indicates that the neurologic functional recovery in the RIPC group is better than that observed in the control group in the early recovery stage. The better recovery ratio in the RIPC group at early stages may provide the chance to combine other recovery measures and finally get an expected outcome. In concert with the findings from previous studies, 8, 9, 23 this small clinical trial suggests that remote preconditioning may be a rational therapeutic strategy to reduce ischemia-reperfusion injury in vulnerable organs in humans.
Although they have been studied extensively in the myocardial ischemia, [24] [25] [26] [27] the protective mechanisms of RIPC on spinal cord ischemia are still unclear. Previous studies suggest that a number of substances, including adenosine, bradykinin, reactive oxygen species, etc, are involved in triggering RIPC. [28] [29] [30] RIPC might exert its protective effect against ischemia on spinal cord through these substances in a humoral pathway. Our recent study has proved that some of the possible substances, such as endocannabinoids, mediate the protective effect of RIPC on spinal cord ischemia in rats. 31 Several studies have used hexamethonium as a probe to investigate the role of the neurogenic pathway in RIPC against ischemic injury, but the results available are inconsistent. 7 Whether these mechanisms are involved in the clinical neuroprotection of RIPC on spinal cord still needs to be clarified.
There are a few limitations to the current work. First, our study may not have sufficient statistical power to test for an effect of RIPC on neurologic outcome from a surgical procedure that has a complication rate in the range of 2% to 5.7%. Although the results showed that RR was recovered faster in the RIPC group than in the control group, the RR data did not show any significant difference between the 2 groups at 6 months after decompression. It indicates that a more sensitive assessment scoring system or a larger number of patients are needed in the future study. Second, a fixed RIPC procedure (three 5-min cycles) was used in the current study. This procedure is referred to in our previous animal experiment results and other clinical reports in cardiac ischemia. However, the multiple designs may optimize the RIPC protocol and get more impressive clinical outcome. Therefore, a dose-response study is required to determine the optimum effective course of RIPC. Third, for technical and ethical reasons, the biomarkers (NSE and S-100B) were only detected in the serum. But, in future studies it would be more reliable to detect these markers in cerebral spinal cord fluid.
In conclusion, the results for markers of neuronal ischemic injury and rate of recovery suggest that a clinical trial with sufficient statistical power to detect an effect of RIPC on the incidence of neurologic complications (paresis, palsy, etc) due to spinal cord ischemia-reperfusion injury after spine surgery is warranted.
